Prior to founding Rx Securities, Samir was a founding partner of Code Securities, a specialist life sciences investment bank which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013. For many years, Nomura Code was the most active adviser in the European healthcare sector, measured by the number of transactions and equity capital raised. Samir has worked as a pan-European biotechnology equity research analyst for 20 years. Prior to Nomura Code he held similar positions at Altium Capital, JP Morgan and Numis Securities. As well as advising institutional fund managers on their healthcare investments, he has significant secondary market fundraising and IPO experience. Samir completed a degree in Pharmacy at London University’s School of Pharmacy and a PhD in pharmaceutical technology at King’s College London.
Michael has worked as a medical technology specialist for over 30 years, within industry and as an equity analyst. He joined Rx Securities in April 2016 as a medical technology analyst having previously worked as part of the healthcare research team at Stifel since 2013. As one of its founding partners, Michael was the medical technology analyst and Head of Research for Nomura Code between 2003 and 2013. Michael initially became an equity analyst in 1997 when he worked within SG/Cowen's healthcare research team and subsequently WestLB Panmure (2000-2003), specialising in the pharmaceutical and biotechnology sectors as well as medical technology. Prior to joining SG Securities in 1997, Michael spent 12 years working in the medical technology industry, working for Amersham International (now GE Healthcare) and Pfizer Hospital Products, initially as a development scientist but mostly in international marketing. He graduated in 1985 with a degree in Biochemistry and Physiology from Southampton University.
Joe is a healthcare analyst for Rx Securities having previously worked as a senior analyst with business intelligence agency Datamonitor Healthcare. During his three years at Datamonitor he worked collaboratively within a number of disease-focussed teams (including oncology, autoimmune and infectious diseases) where he authored therapeutic reports analysing investigational drug pipelines and treatment trends with a particular focus on building and developing patient-based therapeutic sales models. Joe holds BSc and MRes degrees from the University of Birmingham and a PhD in structural and molecular biology from University College London (contributing author to a number of published research articles, including in the prestigious science journal, Nature).
Ross is a healthcare analyst for Rx Securities having joined in September 2019. Previously, he worked as a London-based healthcare equity analyst at Bryan, Garnier & Co in which he provided coverage of European healthcare companies. Prior to this, he worked as an investment associate at Biocity Group, analysing early stage life sciences companies for potential seed investment. Ross holds an MBChB and BMedSci Hons Pharmacology from the University of Edinburgh.
Julian has worked in equity finance for over 40 years, in a career that has ranged from Government privatisations at SG Warburg (now UBS), building an Equity department as Head of Sales at SocGen Securities, to specialist mid and small-cap Corporate Broking at WestLB Panmure. He was then a founding partner and Head of Sales of Code (later Nomura Code) Securities, then Head of Life Sciences at Ambrian Partners, and ran Healthcare Specialist Sales at Stifel Nicolas Europe. Having specialised in Healthcare for twenty years, Julian has been directly involved in the raising of over £3.0bn within the sector through IPOs, M&A, secondary financings and private funding rounds, and has done advisory work for a large range of both quoted and unquoted companies.